19. Stass H,Delesen H,Nagelschmitz J,et al. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis:a phase Ⅰ,randomized,single-dose,dose-escalation study. J Aerosol Med Pulm Drug Deliv,2014.
[2]
1. ？Lin R,Guan R,Liu X,et al. Significant rise of the prevalence and clinical features of childhood asthma in Qingdao China:cluster sampling investigation of 10,082 children. BMC Public Health,2014,14:1002.
[3]
2. Chen ZH,Wang PL,Shen HH. Asthma research in China:a five-year review. Respirology,2013,18 Suppl 3:10-19.
[4]
3. Tu YH,Zhang Y,Fei GH. Utility of the CAT in the therapy assessment of COPD exacerbations in China. BMC Pulm Med,2014,14:42.
[5]
4. He Y,Jiang B,Li LS,et al. Secondhand smoke exposure predicted COPD and other tobacco-related mortality in a 17-year cohort study in China. Chest,2012,142:909-918.
[6]
5. Srichana T,Martin GP,Marriott C. Dry powder inhalers:the influence of device resistance and powder formulation on drug and lactose deposition in vitro. Eur J Pharm Sci,1998,7:73-80.
[7]
6. Suwandecha T,Wongpoowarak W,Srichana T. Computer-aided design of dry powder inhalers using computational fluid dynamics to assess performance. Pharm Dev Technol,2014,1-7.
[8]
7. Chopra N,Oprescu N,Fask A,et al. Does introduction of new "easy to use" inhalational devices improve medical personnel's knowledge of their proper use? Ann Allergy Asthma Immunol,2002,88:395-400.
[9]
8. Azouz W,Chetcuti P,Hosker HS,et al. The inhalation characteristics of patients when they use different dry powder inhalers. J Aerosol Med Pulm Drug Deliv,2015,28:35-42.
[10]
9. Giner J,Torrejon M,Ramos A,et al. Patient preference in the choice of dry powder inhalers. Arch Bronconeumol,2004,40:106-109.
11. Robles J,Motheral L. Hypersensitivity reaction after inhalation of a lactose-containing dry powder inhaler. J Pediatr Pharmacol Ther,2014,19:206-211.
[13]
12. Blair HA,Deeks ED. Umeclidinium/vilanterol:a review of its use as maintenance therapy in adults with chronic obstructive pulmonary disease. Drugs,2015,75:61-74.
[14]
13. Relvar Ellipta for asthma. Drug Ther Bull,2014,52:93-96.
[15]
14. Siler TM,Laforce CF,Kianifard F,et al. Once-daily indacaterol 75 mug in moderate-to-severe COPD:results of a Phase IV study assessing time until patients' perceived onset of effect. Int J Chron Obstruct Pulmon Dis,2014,9:919-925.
[16]
15. O'byrne PM,Woodcock A,Bleecker ER,et al. Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma:a 12-week randomized trial. Respir Res,2014,15:88.
[17]
16. Norris V,Ambery C. Use of propranolol blockade to explore the pharmacology of GSK961081,a bi-functional bronchodilator,in healthy volunteers:results from two randomized trials. Drugs R D,2014,14:241-251.
18. Tulbah AS,Ong HX,Morgan L,et al. Dry powder formulation of simvastatin. Expert Opin Drug Deliv,2014,1-12.
[20]
20. Uttley L,Harnan S,Cantrell A,et al. Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis. Eur Respir Rev,2013,22:476-486.
[21]
21. Belotti S,Rossi A,Colombo P,et al. Spray dried amikacin powder for inhalation in cystic fibrosis patients:a quality by design approach for product construction. Int J Pharm,2014,471:507-515.
[22]
22. Young PM,Salama RO,Zhu B,et al. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. Drug Dev Ind Pharm,2014.
[23]
23. Gangadhar KN,Adhikari K,Srichana T. Synthesis and evaluation of sodium deoxycholate sulfate as a lipid drug carrier to enhance the solubility,stability and safety of an amphotericin B inhalation formulation. Int J Pharm,2014,471:430-438.
[24]
24. Schoubben A,Giovagnoli S,Tiralti MC,et al. Capreomycin inhalable powders prepared with an innovative spray-drying technique. Int J Pharm,2014,469:132-139.
[25]
25. Zarogoulidis P,Chatzaki E,Porpodis K,et al. Inhaled chemotherapy in lung cancer:future concept of nanomedicine. Int J Nanomedicine,2012,7:1551-1572.
